Fusion Peptide Sequence And Sars-Cov

SARS-CoV-2 Spike Peptide

9083P 0.05 mg
EUR 235.5
Description: (NT) SARS-CoV-2 Spike peptide

Human IgG antibody Laboratories manufactures the fusion peptide sequence and sars-cov reagents distributed by Genprice. The Fusion Peptide Sequence And Sars-Cov reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Peptide. Other Fusion products are available in stock. Specificity: Fusion Category: Peptide Group: Sequence And

PLPro Antibody (SARS-CoV)

250 µg
EUR 360
Description: Chicken polyclonal antibody recognizing the SARS-CoV Papain-like Protease (PLpro) as a 35 kDa protein. Purified from egg yolks. This antibody recognizes PLPro from both SARS-CoV-1 and SARS-CoV-2. Does not cross react with SARS-CoV 3CL protease.

SARS-CoV Matrix Antibody

0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Envelope Antibody

0.02 mg
EUR 206.18
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

SARS-CoV Envelope Antibody

0.1 mg
EUR 523.7
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

Sequence And information

SARS-CoV-2 (COVID-19) NSP8 Peptide

9167P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide

9171P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide

9173P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP4 Peptide

9175P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide

SARS-CoV-2 (COVID-19) NSP6 Peptide

9177P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide

SARS-CoV-2 (COVID-19) ORF6 Peptide

9189P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide

SARS-CoV-2 (COVID-19) ORF8 Peptide

9287P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide

SARS-CoV-2 (COVID-19) ORF8 Peptide

9289P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide

SARS-CoV-2 (COVID-19) NSP10 Peptide

9179P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) NSP10 Peptide

SARS-CoV-2 (COVID-19) ORF9b Peptide

9191P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF9b Peptide

SARS-CoV-2 (COVID-19) ORF3a Peptide

9275P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF3a Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide

9277P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide

9279P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide

9281P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF7a Peptide

9283P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide

SARS-CoV-2 (COVID-19) ORF7a Peptide

9285P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide

SARS-CoV-2 (COVID-19) ORF9c Peptide

9291P 0.05 mg
EUR 235.5
Description: SARS-CoV-2 (COVID-19) ORF9c Peptide